Fortress Biotech Inc (FBIO) - Net Assets
Based on the latest financial reports, Fortress Biotech Inc (FBIO) has net assets worth $62.18 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($185.55 Million) and total liabilities ($123.36 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Fortress Biotech Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $62.18 Million |
| % of Total Assets | 33.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | -72.47% |
| 10-Year Change | -25.05% |
| Growth Volatility | 128.81 |
Fortress Biotech Inc - Net Assets Trend (2009–2025)
This chart illustrates how Fortress Biotech Inc's net assets have evolved over time, based on quarterly financial data. Also explore total assets of Fortress Biotech Inc for the complete picture of this company's asset base.
Annual Net Assets for Fortress Biotech Inc (2009–2025)
The table below shows the annual net assets of Fortress Biotech Inc from 2009 to 2025. For live valuation and market cap data, see Fortress Biotech Inc (FBIO) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $62.18 Million | +3882.42% |
| 2024-12-31 | $-1.64 Million | -203.59% |
| 2023-12-31 | $1.59 Million | -96.83% |
| 2022-12-31 | $50.02 Million | -77.85% |
| 2021-12-31 | $225.88 Million | +14.66% |
| 2020-12-31 | $197.00 Million | +171.60% |
| 2019-12-31 | $72.53 Million | +267.38% |
| 2018-12-31 | $19.74 Million | -83.62% |
| 2017-12-31 | $120.50 Million | +45.24% |
| 2016-12-31 | $82.97 Million | -1.55% |
| 2015-12-31 | $84.27 Million | +19.50% |
| 2014-12-31 | $70.52 Million | -13.23% |
| 2013-12-31 | $81.28 Million | +268.89% |
| 2012-12-31 | $22.03 Million | +15.16% |
| 2011-12-31 | $19.13 Million | +42.99% |
| 2010-12-31 | $13.38 Million | +232.61% |
| 2009-12-31 | $-10.09 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fortress Biotech Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 72382000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $32.00K | 0.06% |
| Other Components | $783.89 Million | 1571.78% |
| Total Equity | $49.87 Million | 100.00% |
Fortress Biotech Inc Competitors by Market Cap
The table below lists competitors of Fortress Biotech Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Hipages Group Holdings Ltd
AU:HPG
|
$75.07 Million |
|
Westwater Resources Inc
NYSE MKT:WWR
|
$75.08 Million |
|
Transat AT Inc
TO:TRZ
|
$75.11 Million |
|
American Tungsten & Antimony Ltd
AU:AT4
|
$75.12 Million |
|
Tuniu Corporation
F:0TUA
|
$75.01 Million |
|
Suominen Oyj
HE:SUY1V
|
$74.97 Million |
|
Birlesim Muhendislik Isitma Sogutma Havalandirma Sanayi & Ticaret Sirketi AS
IS:BRLSM
|
$74.95 Million |
|
Seoul Auction Co. Ltd
KQ:063170
|
$74.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fortress Biotech Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 22,737,000 to 49,873,000, a change of 27,136,000 (119.3%).
- Net income of 6,815,000 contributed positively to equity growth.
- Dividend payments of 664,000 reduced retained earnings.
- Share repurchases of 265,000 reduced equity.
- New share issuances of 81,681,000 increased equity.
- Other factors decreased equity by 60,431,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $6.82 Million | +13.66% |
| Dividends Paid | $664.00K | -1.33% |
| Share Repurchases | $265.00K | -0.53% |
| Share Issuances | $81.68 Million | +163.78% |
| Other Changes | $-60.43 Million | -121.17% |
| Total Change | $- | 119.35% |
Book Value vs Market Value Analysis
This analysis compares Fortress Biotech Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.04x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | $-41.89 | $2.33 | x |
| 2010-12-31 | $2.27 | $2.33 | x |
| 2011-12-31 | $2.50 | $2.33 | x |
| 2012-12-31 | $15.26 | $2.33 | x |
| 2013-12-31 | $40.07 | $2.33 | x |
| 2014-12-31 | $29.12 | $2.33 | x |
| 2015-12-31 | $32.29 | $2.33 | x |
| 2016-12-31 | $14.45 | $2.33 | x |
| 2017-12-31 | $18.93 | $2.33 | x |
| 2018-12-31 | $0.64 | $2.33 | x |
| 2019-12-31 | $7.19 | $2.33 | x |
| 2020-12-31 | $20.90 | $2.33 | x |
| 2021-12-31 | $19.95 | $2.33 | x |
| 2022-12-31 | $7.04 | $2.33 | x |
| 2023-12-31 | $2.78 | $2.33 | x |
| 2024-12-31 | $1.09 | $2.33 | x |
| 2025-12-31 | $0.18 | $2.33 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fortress Biotech Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.66%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.77%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 3.72x
- Recent ROE (13.66%) is above the historical average (-368.20%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.66 Million |
| 2010 | -74.60% | 0.00% | 0.00x | 1.12x | $-11.32 Million |
| 2011 | -190.05% | 0.00% | 0.00x | 1.22x | $-38.27 Million |
| 2012 | -125.31% | 0.00% | 0.00x | 1.86x | $-29.81 Million |
| 2013 | -45.72% | 0.00% | 0.00x | 1.24x | $-45.29 Million |
| 2014 | -28.91% | 0.00% | 0.00x | 1.27x | $-27.44 Million |
| 2015 | -57.47% | -5611.59% | 0.01x | 1.41x | $-56.86 Million |
| 2016 | -143.12% | -334.31% | 0.10x | 4.44x | $-58.94 Million |
| 2017 | -127.21% | -35.65% | 0.76x | 4.68x | $-72.13 Million |
| 2018 | -4543.57% | -313.02% | 0.19x | 76.13x | $-84.33 Million |
| 2019 | -152.43% | -109.09% | 0.16x | 8.64x | $-42.58 Million |
| 2020 | -46.37% | -102.03% | 0.14x | 3.32x | $-56.56 Million |
| 2021 | -59.54% | -94.06% | 0.17x | 3.65x | $-75.57 Million |
| 2022 | -207.51% | -114.30% | 0.26x | 7.05x | $-90.75 Million |
| 2023 | -268.97% | -71.75% | 0.50x | 7.43x | $-62.89 Million |
| 2024 | -202.30% | -79.75% | 0.40x | 6.34x | $-48.27 Million |
| 2025 | 13.66% | 10.77% | 0.34x | 3.72x | $1.83 Million |
Industry Comparison
This section compares Fortress Biotech Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fortress Biotech Inc (FBIO) | $62.18 Million | 0.00% | 1.98x | $75.03 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Fortress Biotech Inc
Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe reca… Read more